The Therapeutic Action of Lorazepam

1903 Words4 Pages

Lorazepam: The Liver’s BFF

Pharmacodynamics

Lorazepam or better know as Ativan belongs to the benzodiazepine family and produces inhibitory effects in the central nervous system. The therapeutic action of Lorazepam happens with the interaction at the benzodiazepine binding sites. These binding sites are located on the inotropic gamma-amino butyric acid-A (GABAA) receptors. The neurotransmitter used by Lorazepam is the inhibitory neurotransmitter GABA. Lorazepam and other benzodiazepines do not bind directly to the same receptor site as the endogenous GABA neurotransmitter does. As you can see from Figure 1 they bind to the benzodiazepine binding sites located in between the alpha and gamma subunits on the GABAA receptors. Once the benzodiazepine locks into the GABAA receptor it alters it, so the neurotransmitter GABA has a much higher affinity for it. Lorazepam doesn’t mimic the effects of GABA, but instead enhances GABA’s affinity for the GABAA receptor. Lorazepam doesn’t directly open the chloride gates itself. The GABA neurotransmitter is what opens the gates. With the higher affinity is becomes a pulsing motion of the gate opening and closing rendering its effects of more chloride being let in.

When GABA normally binds to the GABAA receptor it opens a chloride channel allowing chloride to rush in. When Lorazepam binds to the benzodiazepine site on the GABAA receptor it increases the rate at which the chloride channel opens when GABA attaches to them. This allows an increase in the concentration of chloride ions in the cell. This effect results in hyper-polarizing the cell making it highly negative inside, which makes it less excitable. This reversal potential of the chloride ions inhibits the firing of any new action potent...

... middle of paper ...

...
When the patient suffers from anxiety or alcohol withdrawals they receive the same dose. It is given sublingually at the dose of 2-6 mg. If the patient is in status epilepticcus then the recommend dose is 0.05 mg/kg to a max of 4 mg by a slow intravenous push. This dose is able to be repeated once in a 12 hour period. (Wyeth & Ayerst)

Local protocols may differ from this does and medical directors can decide which dose of the medication they prefer to be given. As you can see from Table 1 the dose recommend by Alberta Health Services is 1 mg sublingually and may be repeated once. More can be administered but consultation with on-line medical control would have to be done.

Lorazepam - Alcohol Withdrawal and Non-Aggressive Psychiatric

Table 1: AHS Protocols
(https://www.ahsems.com/secure/protocols/1#view/5042/Notes)

(Saari, Uusi-Oukari, Ahonen & Olkkola , 2011)

More about The Therapeutic Action of Lorazepam

Open Document